The CEOs of Eli Lilly and Novo Nordisk — rivals in the GLP-1 obesity market — addressed nagging questions at the 2024 J.P. Morgan Healthcare Conference.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,